| CVALF Stock | | | USD 2.54 0.05 1.93% |
CEO
Mr. Brian E. Pedlar is President, Chief Executive Officer, Director of Covalon Technologies Ltd. He was Interim Chief Financial Officer of the Company effective January 9, 2013. He was member of the Board of Directors since January 14, 2010. Previously, Mr. Pedlar was President of Pedlar Ventures Limited, a private venture investment and consulting firm based in Oakville, Ontario. He has served in senior executive positions with public companies including temporary CFO, Cygnal Technologies Corporationration, October 2007 President, Cedara Software Corporationration, 2005 to 2006 Chief Financial Officer, Cedara Software Corporationration, 2004 to 2005 and Director of Finance, Cedara Software Corporationration, 2000 to 2004. Mr. Pedlar has also held senior executive positions with Merge Healthcare and IMAX Corporation since 2015.
| Tenure | 9 years |
| Phone | 905 568 8400 |
| Web | https://www.covalon.com |
Pedlar holds a BS degree from Mount Allison University, a postgraduate diploma in Accounting from Wilfrid Laurier University and is a Canadian Chartered Accountant.
Covalon Technologies Management Efficiency
The company has return on total asset
(ROA) of
(0.161) % which means that it has lost $0.161 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.3213) %, meaning that it generated substantial loss on money invested by shareholders. Covalon Technologies' management efficiency ratios could be used to measure how well Covalon Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
Covalon Technologies has accumulated 2.25
M in total debt with debt to equity ratio
(D/E) of 0.08, which may suggest the company is not taking enough advantage from borrowing. Covalon Technologies has a current ratio of 9.84, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Covalon Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Covalon Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Covalon Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Covalon to invest in growth at high rates of return. When we think about Covalon Technologies' use of debt, we should always consider it together with cash and equity.
Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. It serves hospitals, wound care centers, burn centers, extendedalternate care and acute care facilities, home health care agencies, and physicians offices. Covalon Tech operates under Biotechnology classification in the United States and is traded on OTC Exchange. Covalon Technologies [CVALF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Management Performance
Covalon Technologies Leadership Team
Elected by the shareholders, the Covalon Technologies' board of directors comprises two types of representatives: Covalon Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Covalon. The board's role is to monitor Covalon Technologies' management team and ensure that shareholders' interests are well served. Covalon Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Covalon Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Valerio DiTizio, Co-Founder and Chief Science Officer | |
| Simon Smith, Chief Ltd | |
| Brian Pedlar, CEO and President and Director | |
| Ron Hebert, VP Marketing | |
| Greg Leszczynski, VP HR | |
| Hamed Abbasian, VP Devel | |
| Gerry Arambula, Pres Ltd | |
| Jason Gorel, Interim Officer | |
| Elaine Zhang, VP Operations | |
| Mark Doolittle, VP Sales | |
Covalon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Covalon Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Covalon OTC Stock
Covalon Technologies financial ratios help investors to determine whether Covalon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Covalon with respect to the benefits of owning Covalon Technologies security.